Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in NTDT
NCT02995707Phase 2Unknown
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in thalassemia. Primary endpoint: The level of Hemoglobin at 18 months. Status: unknown.
02
Drugs
thalidomide
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT02995707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02995707.